In 2016, Liu et al16 found that the activity of PREX1-Rac-GEF is crucial for the growth of cells dependent on Prex1 and the growth of transplanted tumors, and it may become a therapeutic target for breast cancer. This evidence concerns the gene AKT1 and breast cancer.